Iksuda Therapeutics
Iksuda Therapeutics focuses on developing antibody-drug conjugates (ADCs) with enhanced tumor specificity for difficult-to-treat cancers. They have a research and development team working on a pipeline of ADCs aimed at anti-cancer effectiveness and patient outcomes.
- Bioconjugation technologies
- Antibody-drug conjugates (ADCs)
- Tumour-selective payload activation